Пређи на садржај

Nifedipin

С Википедије, слободне енциклопедије
(преусмерено са Nifedipine)
Nifedipin
Klinički podaci
Prodajno imeAdalat, Adalat 10, Adalat 20, Adalat 5
Drugs.comMonografija
Način primeneOralno
Farmakokinetički podaci
Poluvreme eliminacije2 h
Identifikatori
CAS broj21829-25-4 ДаY
ATC kodC08CA05 (WHO)
PubChemCID 4485
IUPHAR/BPS2514
DrugBankDB01115 ДаY
ChemSpider4330 ДаY
KEGGC07266 ДаY
ChEBICHEBI:7565 ДаY
ChEMBLCHEMBL193 ДаY
Hemijski podaci
FormulaC17H18N2O6
Molarna masa346,335
  • COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC
  • InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 ДаY
  • Key:HYIMSNHJOBLJNT-UHFFFAOYSA-N ДаY
Fizički podaci
Tačka topljenja172—174 °C (342—345 °F)

Nifedipin je organsko jedinjenje, koje sadrži 17 atoma ugljenika i ima molekulsku masu od 346,335 Da.[1][2][3][4][5][6][7][8]

Osobina Vrednost
Broj akceptora vodonika 7
Broj donora vodonika 1
Broj rotacionih veza 6
Particioni koeficijent[9] (ALogP) 1,8
Rastvorljivost[10] (logS, log(mol/L)) -4,2
Polarna površina[11] (PSA, Å2) 110,5
  1. ^ Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 Jul 29;356(9227):366-72. PMID 10972368
  2. ^ Poole-Wilson PA, Kirwan BA, Voko Z, de Brouwer S, van Dalen FJ, Lubsen J: Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs Ther. 2006 Feb;20(1):45-54. PMID 16552473
  3. ^ Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A, Libersa C, Robert H: Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharm Ther. 2005 Apr;30(2):153-8. PMID 15811168
  4. ^ Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996 Oct 23-30;276(16):1328-31. PMID 8861992
  5. ^ Takahashi D, Oyunzul L, Onoue S, Ito Y, Uchida S, Simsek R, Gunduz MG, Safak C, Yamada S: Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Biol Pharm Bull. 2008 Mar;31(3):473-9. PMID 18310913
  6. ^ Varon J, Marik PE: Clinical review: the management of hypertensive crises. Crit Care. 2003 Oct;7(5):374-84. Epub 2003 Jul 16. PMID 12974970
  7. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126.  уреди
  8. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958.  уреди
  9. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  10. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.  уреди
  11. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.  уреди

Spoljašnje veze

[уреди | уреди извор]


Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).